Browsing: Novo

Intent on growing its leading position in obesity and weight management drugs, Novo Nordisk has made an unsolicited, approximately up-to-$9…

If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B)…

Danish biosolutions company Novonesis and healthcare company Novo Nordisk have entered a research partnership to explore the role of the…

Novo Nordisk (NASDAQ Copenhagen: NOVO-B) inflicted much pain—and much-needed pain—on the company when president and CEO Maziar (Mike) Doustdar announced…

The Danish firms plan to develop and test synbiotic dietary supplements – combining probiotics and prebiotics – that can have…